Oocyte

INVO Bioscience to Report First Quarter 2022 Financial Results on Monday, May 16, 2022

Retrieved on: 
Monday, May 9, 2022
Private Securities Litigation Reform Act, Insemination, IVF, NASDAQ, ART, Oocyte, Fertilisation, Company, Securities Exchange Act of 1934, Securities Act of 1933, Patient, Investor relations, IVC, Fertility clinic, IUI, Financial result

SARASOTA, Fla., May 9, 2022 /PRNewswire/ -- INVO Bioscience, Inc. (NASDAQ: INVO), a commercial-stage fertility company focused on expanding access to advanced treatment worldwide with its INVOcell® medical device and the IVC procedure it enables, will report financial results for its first quarter 2022, ended March 31, 2022, after the market close on Monday, May 16, 2022. The Company has scheduled a conference call that same day, Monday, May 16, 2022, at 4:30 pm ET, to review the results.

Key Points: 
  • Financial results to be released after market close;
    SARASOTA, Fla., May 9, 2022 /PRNewswire/ -- INVO Bioscience, Inc. (NASDAQ: INVO), a commercial-stage fertility company focused on expanding access to advanced treatment worldwide with its INVOcell medical device and the IVC procedure it enables, will report financial results for its first quarter 2022, ended March 31, 2022, after the market close on Monday, May 16, 2022.
  • The Company has scheduled a conference call that same day, Monday, May 16, 2022, at 4:30 pm ET, to review the results.
  • Replay:A teleconference replay of the call will be available through May 23, 2022, at 877-344-7529 or 412-317-0088, replay access code # 4725753.
  • A webcast replay will be available in the Investor Relations section of the Company's website at https://www.invobioscience.com/investors/ for 90 days.

INVO Celebrates National Infertility Awareness Week at the INVO Center in Atlanta, Georgia

Retrieved on: 
Thursday, April 28, 2022
IVF, Securities Exchange Act of 1934, IVC, ART, Patient, IUI, Fertilisation, Private Securities Litigation Reform Act, Oocyte, Securities Act of 1933, Company, Multimedia, Fertility clinic, Insemination, Birth control

SARASOTA, Fla., April 28, 2022 /PRNewswire/ -- INVO Bioscience, Inc. (NASDAQ: INVO), a commercial-stage fertility company focused on expanding access to advanced treatment worldwide with its INVOcell® medical device and the intravaginal culture ("IVC") procedure it enables, today announced that in celebration of this year's National Infertility Awareness Week ("NIAW"), three eligible patients will be granted a full IVC treatment cycle free of charge.  The grant program, including patient selection, will be launched in the coming weeks.  NIAW is a movement, founded in 1989 by RESOLVE, with a mission to empower patients and help those struggling to build a family.

Key Points: 
  • Our flagship product is INVOcell, a revolutionary medical device that allows fertilization and early embryo development to take place in vivo within the woman's body.
  • Our primary mission is to implement new medical technologies aimed at increasing the availability of affordable, high-quality, patient-centered fertility care.
  • This treatment solution is the world's first intravaginal culture technique for the incubation of oocytes and sperm during fertilization and early embryo development.
  • This technique, designated as "IVC", provides patients a more natural, intimate, and more affordable experience in comparison to other ART treatments.

INVO Selects Kansas City as additional INVO Center Location

Retrieved on: 
Thursday, April 14, 2022
CEO, Fertility clinic, NASDAQ, Infertility, ART, Private Securities Litigation Reform Act, Patient, Securities Act of 1933, Securities Exchange Act of 1934, Company, IVC, IUI, Insemination, Fertilisation, IVF, Multimedia, Oocyte, Pharmaceutical industry, Kansas City metropolitan area

SARASOTA, Fla., April 14, 2022 /PRNewswire/ -- INVO Bioscience, Inc. (NASDAQ: INVO) ("INVO" or the "Company"), a commercial-stage fertility company focused on expanding access to advanced treatment worldwide with its INVOcell® medical device and the intravaginal culture ("IVC") procedure it enables, today announced plans to open an INVO Center in Kansas City, Missouri. The Kansas City INVO Center will focus on patients in need of advanced fertility care utilizing the efficient, effective, and affordable INVOcell® solution. The Company currently has three operational INVO Centers treating patients in Birmingham, Alabama, Atlanta, Georgia, and Monterrey, Mexico, with others scheduled to open in the San Francisco and Tampa areas.

Key Points: 
  • The Kansas City INVO Center will focus on patients in need of advanced fertility care utilizing the efficient, effective, and affordable INVOcell solution.
  • "We are excited to announce Kansas City as another ideal location for an INVO Center," commented Steve Shum, CEO of INVO.
  • "We are refining the process involved in opening an INVO Center and are executing these initiatives simultaneously to improve operational timelines and revenue ramp.
  • Similar to other INVO Centers, the Company expects to engage physician partners to support its efforts in the Kansas City market.

Eggschain CEO to Speak on Blockchain Applications in Fertility Treatment at 2022 College of Reproductive Biology Symposium

Retrieved on: 
Thursday, April 14, 2022
Health, Technology, Other Technology, Other Health, General Health, Pharmaceutical, Biotechnology, Convention center, CEO, AMS, DNA, Public health, Association, College, National, AT, CRB, AAB, Science, RNA, Fertility, Egg, Tissue, American Association of Bioanalysts, Conference, Blood, Environmental science, Reproductive biology, Genome, Technology, Embryology, IVF, American Association, Partnership, B cell, Oocyte, Endocrinology, Andrology, Knowledge, Vaccine

CRBs educational programs have been well received within the field of assisted reproductive technology by clinic staff and laboratory personnel.

Key Points: 
  • CRBs educational programs have been well received within the field of assisted reproductive technology by clinic staff and laboratory personnel.
  • Symposium attendees are reproductive biologists and include laboratory directors, technical supervisors, clinical consultants, and andrology and embryology laboratory scientists.
  • Eggschain is a healthcare technology company and thought leader in the fertility, health tech, family-building and cryogenic preservation industries.
  • AABs specialized membership sections include the College of Reproductive Biology (CRB), AAB Associate Member Section (AMS), Environmental Biology and Public Health (EBPH) Section, and the National Independent Laboratory Association (NILA).

INVO Bioscience to Participate in the Lytham Partners Spring 2022 Investor Conference

Retrieved on: 
Monday, April 4, 2022
Company, Private Securities Litigation Reform Act, Fertilisation, Oocyte, NASDAQ, Multimedia, Structure of the Spanish Air Force, IUI, Insemination, Conference, IVC, IVF, Fertility clinic, Securities Exchange Act of 1934, Securities Act of 1933, ART, Patient, Video game, Birth control

SARASOTA, Fla., April 4, 2022 /PRNewswire/ -- INVO Bioscience, Inc. (NASDAQ: INVO), a commercial-stage fertility company focused on expanding access to advanced treatment worldwide with its INVOcell medical device and the intravaginal culture ("IVC") procedure it enables, announced today that it will be participating in the Lytham Partners Spring 2022 Investor Conference taking place virtually on April 4-7, 2022.

Key Points: 
  • SARASOTA, Fla., April 4, 2022 /PRNewswire/ -- INVO Bioscience, Inc. (NASDAQ: INVO), a commercial-stage fertility company focused on expanding access to advanced treatment worldwide with its INVOcell medical device and the intravaginal culture ("IVC") procedure it enables, announced today that it will be participating in the Lytham Partners Spring 2022 Investor Conference taking place virtually on April 4-7, 2022.
  • The Company's webcast presentation will be available for viewing at 11:00am ET on Monday, April 4, 2022, on the Company's website orat https://wsw.com/webcast/lytham4/invo/2054868 .
  • To arrange a meeting with management, please contact Lytham Partners at [email protected] or register at www.lythampartners.com/spring2022invreg .
  • Our primary mission is to implement new medical technologies aimed at increasing the availability of affordable, high-quality, patient-centered fertility care.

INVO Bioscience to Exhibit at the 2022 Pacific Coast Reproductive Society (PCRS) Annual Meeting

Retrieved on: 
Thursday, March 24, 2022
Business development, Company, Private Securities Litigation Reform Act, Fertilisation, Assisted reproductive technology, Oocyte, NASDAQ, Multimedia, CME, Doctor of Philosophy, IUI, CEO, IVC, IVF, Senior, Continuing medical education, Fertility clinic, Securities Exchange Act of 1934, Annual general meeting, Securities Act of 1933, CA, ART, Physician, Reproductive medicine, Maritime Transportation Security Act of 2002, VP, Patient, Pharmaceutical industry, Birth control

SARASOTA, Fla., March 24, 2022 /PRNewswire/ -- INVO Bioscience, Inc. (NASDAQ: INVO), developers of the INVOcell, an advanced fertility treatment technology which is currently available, is exhibiting the INVOcell solution at the 2022 Pacific Coast Reproductive Society (PCRS) Annual Meeting, taking place March 23-27 at the Renaissance Esmeralda Resort & Spa in Indian Wells, CA.

Key Points: 
  • SARASOTA, Fla., March 24, 2022 /PRNewswire/ -- INVO Bioscience, Inc. (NASDAQ: INVO), developers of the INVOcell, an advanced fertility treatment technology which is currently available, is exhibiting the INVOcell solution at the 2022 Pacific Coast Reproductive Society (PCRS) Annual Meeting, taking place March 23-27 at the Renaissance Esmeralda Resort & Spa in Indian Wells, CA.
  • Pacific Coast Reproductive Society is a multidisciplinary medical specialty society providing Continuing Medical Education (CME) to physicians and allied healthcare professionals.
  • The PCRS Annual Meeting provides an outstanding forum for the exchange of information and the advancement of the ideologies of reproductive medicine in a relaxed and collegial setting.
  • Session topics have been carefully selected to bring you the highest quality, innovative CME, designed and presented by thought leaders in reproductive medicine.

INVO Bioscience to Participate in Roundtable Discussion at the 2022 Virtual Growth Conference Presented by Maxim Group LLC and Hosted by M-Vest

Retrieved on: 
Tuesday, March 22, 2022
Charles M. Vest, Company, Private Securities Litigation Reform Act, Oocyte, NASDAQ, Multimedia, Financial services, Biotechnology, Doctor of Philosophy, Medical Affairs Bureau, IUI, Conference, Q&A, Commercial, IVC, IVF, Women's health, Fertility clinic, Primary energy, Chief executive officer, Securities Exchange Act of 1934, Securities Act of 1933, Belterra Park Gaming & Entertainment Center, ART, Health information technology, Employee Retirement Income Security Act of 1974, Patient, Pharmaceutical industry, Health care

The roundtable, titled "Advances in Women's Health: From Clinical to Commercial" will be webcast live on Monday, March 28th at 3:00pm.

Key Points: 
  • The roundtable, titled "Advances in Women's Health: From Clinical to Commercial" will be webcast live on Monday, March 28th at 3:00pm.
  • The conference will feature company presentations, fireside chats, roundtable discussions, and live Q&A with CEOs moderated by Maxim Research Analysts.
  • Click Here to Reserve your seat
    We are a commercial-stage fertility company expanding access to advanced treatment worldwide.
  • Our primary mission is to implement new medical technologies aimed at increasing the availability of affordable, high-quality, patient-centered fertility care.

Eggschain to Open Auction for First Publicly Available Sperm Account on Blockchain

Retrieved on: 
Wednesday, March 16, 2022
Technology, Women, Security, Genetics, Men, Networks, Biotechnology, Consumer, Health, Data Management, Oocyte, B cell, Egg, Patient, Partnership, NFT, Endocrinology, Sale, Fertility, Tissue, Genetics, CEO, Blood, Genome, IVF, Culture, DNA, RNA, Auction, Cryptocurrency, Blockchain

For a chance to win this historic prize, auction participants will place bids on an exclusive NFT that Eggschain will drop - the winning bid for the NFT will also secure the sperm account.

Key Points: 
  • For a chance to win this historic prize, auction participants will place bids on an exclusive NFT that Eggschain will drop - the winning bid for the NFT will also secure the sperm account.
  • This auction is an opportunity to demystify fertility treatments, participate in crypto culture, and learn more about the blockchain and Eggschain.
  • The below is the description that will accompany the NFT on blockchain:
    This NFT is a unique artistic expression of Eggschain and sperm, but also the first publicly available spot for his sperm on blockchain, via Eggschain, and a history-making moment of his own.
  • This NFT auction is an opportunity to demystify fertility treatments, participate in crypto culture, and/or learn more about Blockchain and Eggschain.

New Birmingham INVO Center Offers Families an Affordable Advanced Fertility Treatment Solution to Help Combat Rising Costs

Retrieved on: 
Thursday, March 10, 2022
NASDAQ, DNP, Social Security Act 1938, Pregnancy, Securities Act of 1933, Fertilisation, Private Securities Litigation Reform Act, Company, IVC, Fertility clinic, OBGYN, IVF, Innovation, IUI, Fertility, Multimedia, Securities Exchange Act of 1934, Patient, Oocyte, ART, Solution, Program, Insurance, Review, Travel, Medical device, Health insurance, Birth control

SARASOTA, Fla., March 10, 2022 /PRNewswire/ -- INVO Bioscience, Inc. (NASDAQ: INVO), developers of the INVOcell, an advanced fertility treatment technology which is currently available through a number of channels, including its new joint-venture owned INVO Center in Birmingham, Alabama, highlights an initiative to continuously provide transparent and affordable advanced fertility treatment solutions to combat rising patient costs.

Key Points: 
  • SARASOTA, Fla., March 10, 2022 /PRNewswire/ -- INVO Bioscience, Inc. (NASDAQ: INVO), developers of the INVOcell, an advanced fertility treatment technology which is currently available through a number of channels, including its new joint-venture owned INVO Center in Birmingham, Alabama, highlights an initiative to continuously provide transparent and affordable advanced fertility treatment solutions to combat rising patient costs.
  • "In today's inflationary market environment, we believe it is more important than ever to drive home the benefits of the affordable and effective INVOcell advanced fertility treatment solution," commented INVO CEO, Steve Shum.
  • This further demonstrates our key initiative to remain focused on the democratization of fertility through the use of our revolutionary INVOcell solution."
  • Currently, at the Birmingham INVO Center, the all-in cost of an IVC (intravaginal culture) procedure is generally less than $7,000.

INVO to Launch Additional INVO Center in Tampa, Florida

Retrieved on: 
Wednesday, February 16, 2022
NASDAQ, ART, Patient, CEO, Company, IVF, IUI, Securities Act of 1933, Private Securities Litigation Reform Act, IVC, Securities Exchange Act of 1934, Fertility clinic, Oocyte, Fertilisation, Multimedia

The Tampa INVO Center will focus on patients in need of advanced fertility care utilizing the efficient, effective, and affordable INVOcell solution.

Key Points: 
  • The Tampa INVO Center will focus on patients in need of advanced fertility care utilizing the efficient, effective, and affordable INVOcell solution.
  • "Following significant diligence and in consultation with industry experts, we are excited to announce Tampa as the next INVO Center location," commented Steve Shum, CEO of INVO.
  • "The characteristics and demographics of the Tampa market lend themselves perfectly to our INVO Center approach focused on expanding access to advanced fertility services for the significantly underserved patient population.
  • We are also actively conducting due diligence in several other markets as we look to initiate further expansion of our INVO Center commercialization platform."